MagnifEye production contract with the UK’s Department of Health & Social Care

Sensyne Health has announced it has signed a production contract with the UK’s Department of Health & Social Care (DHSC) to use Sensyne’s MagnifEye AI technology for reading COVID-19 lateral flow diagnostic tests as part of the UK government’s asymptomatic testing program.

The scope of this contract with DHSC is for a phased national roll-out over a three-month period in care homes, GP practices, and selected private sector organizations with large workforces. Revenues will be shared with Excalibur Healthcare Services Limited under the terms of the exclusive agreement between the two companies.

Lord (Paul) Drayson Ph.D., CEO of Sensyne Health, said, “This is a significant commercial milestone in Sensyne’s development and underlines the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Dept of Health & Social Care to support the UK’s national COVID testing program, which is making a huge impact in helping the nation to recover from the pandemic.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>